Evidence map›Paper›PMID 39186192›Full record

ArticleInsights into imaging2024

CT-based multimodal deep learning for non-invasive overall survival prediction in advanced hepatocellular carcinoma patients treated with immunotherapy.

Yujia Xia, Jie Zhou, Xiaolei Xun, Jin Zhang, Ting Wei, Ruitian Gao, Bobby Reddy, Chao Liu, Geoffrey Kim, Zhangsheng Yu

Abstract read
In one paragraph

Article in Insights into imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Machine learning methods for histopathological image analysis: Updates in 2024.Computational and structural biotechnology journal · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yujia XiaDepartment of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
Jie ZhouSJTU-Yale Joint Center for Biostatistics and Data Science, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
Xiaolei XunStatistics in Global Statistics and Data Science, Beigene, Shanghai, China.
Jin ZhangPiHealth USA, Cambridge, MA, USA.
Ting WeiDepartment of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
Ruitian GaoDepartment of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
Bobby ReddyPiHealth USA, Cambridge, MA, USA.
Chao LiuPiHealth USA, Cambridge, MA, USA.
Geoffrey KimPiHealth USA, Cambridge, MA, USA.
Zhangsheng YuDepartment of Bioinformatics and Biostatistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China. yuzhangsheng@sjtu.edu.cn.ORCID http://orcid.org/0000-0002-8189-5330

Funding

National Natural Science Foundation of China 12171318Science and Technology Innovation Plan Of Shanghai Science and Technology Commission 21ZR1436300Shanghai Jiao Tong University STAR Grant 20190102
6 · The paper itself

Abstract

objectivesTo develop a deep learning model combining CT scans and clinical information to predict overall survival in advanced hepatocellular carcinoma (HCC).

methodsThis retrospective study included immunotherapy-treated advanced HCC patients from 52 multi-national in-house centers between 2018 and 2022. A multi-modal prognostic model using baseline and the first follow-up CT images and 7 clinical variables was proposed. A convolutional-recurrent neural network (CRNN) was developed to extract spatial-temporal information from automatically selected representative 2D CT slices to provide a radiological score, then fused with a Cox-based clinical score to provide the survival risk. The model's effectiveness was assessed using a time-dependent area under the receiver operating curve (AUC), and risk group stratification using the log-rank test. Prognostic performances of multi-modal inputs were compared to models of missing modality, and the size-based RECIST criteria.

resultsTwo-hundred seven patients (mean age, 61 years ± 12 [SD], 180 men) were included. The multi-modal CRNN model reached the AUC of 0.777 and 0.704 of 1-year overall survival predictions in the validation and test sets. The model achieved significant risk stratification in validation (hazard ratio [HR] = 3.330, p = 0.008), and test sets (HR = 2.024, p = 0.047) based on the median risk score of the training set. Models with missing modalities (the single-modal imaging-based model and the model incorporating only baseline scans) can still achieve favorable risk stratification performance (all p < 0.05, except for one, p = 0.053). Moreover, results proved the superiority of the deep learning-based model to the RECIST criteria.

conclusionDeep learning analysis of CT scans and clinical data can offer significant prognostic insights for patients with advanced HCC. CRITICAL RELEVANCE STATEMENT: The established model can help monitor patients' disease statuses and identify those with poor prognosis at the time of first follow-up, helping clinicians make informed treatment decisions, as well as early and timely interventions. KEY POINTS: An AI-based prognostic model was developed for advanced HCC using multi-national patients. The model extracts spatial-temporal information from CT scans and integrates it with clinical variables to prognosticate. The model demonstrated superior prognostic ability compared to the conventional size-based RECIST method.

Indexed as

Computed tomographyDeep learningMulti-modalPrognostic predictionsUnresectable hepatocellular carcinoma

Identifiers

PMID39186192
PMCPMC11347550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.